Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide
- 1 July 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (7), 2693-2696
- https://doi.org/10.1128/aac.48.7.2693-2696.2004
Abstract
Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 μM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.Keywords
This publication has 7 references indexed in Scilit:
- Enteric involvement of severe acute respiratory syndrome-associated coronavirus infectionGastroenterology, 2003
- Update: severe acute respiratory syndrome--United States, June 18, 2003.2003
- A Novel Coronavirus Associated with Severe Acute Respiratory SyndromeThe New England Journal of Medicine, 2003
- A Major Outbreak of Severe Acute Respiratory Syndrome in Hong KongThe New England Journal of Medicine, 2003
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003
- Use of an Aqueous Soluble Tetrazolium/Formazan Assay for Cell Growth Assays in CultureCancer Communications, 1991
- AnthelminticsDrugs, 1977